Taysha Gene Therapies (TSHA) Other Accumulated Expenses (2019 - 2026)

Taysha Gene Therapies (TSHA) has 8 years of Other Accumulated Expenses data on file, last reported at $784000.0 in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses fell 2.73% year-over-year to $784000.0; the trailing twelve-month figure through Mar 2026 stood at $784000.0 (down 2.73% YoY), and the FY2025 full-year result was $777000.0, up 3.32% from the prior year.
• Other Accumulated Expenses advanced to $784000.0 in Q1 2026, from $777000.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $1.6 million in Q1 2022 to a low of $650000.0 in Q4 2022.
• A 5-year average of $892588.2 and a median of $777000.0 in 2024 frame the typical range for Other Accumulated Expenses.
• Across the five-year window, Other Accumulated Expenses jumped 1139.06% in 2022 and tumbled 56.9% in 2023, its largest moves.
• Tracing TSHA's Other Accumulated Expenses over 5 years: stood at $650000.0 in 2022, then advanced by 11.23% to $723000.0 in 2023, then rose by 4.01% to $752000.0 in 2024, then increased by 3.32% to $777000.0 in 2025, then advanced by 0.9% to $784000.0 in 2026.
• Business Quant data shows TSHA's Other Accumulated Expenses at $784000.0 in Q1 2026, $777000.0 in Q4 2025, and $749000.0 in Q3 2025.